Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
SEC Accession No. 0001193125-22-250139
Filing Date
2022-09-23
Accepted
2022-09-23 16:08:39
Documents
13
Effectiveness Date
2022-09-23

Document Format Files

Seq Description Document Type Size
1 S-3ASR d382928ds3asr.htm S-3ASR 422185
2 EX-4.4 d382928dex44.htm EX-4.4 339512
3 EX-4.5 d382928dex45.htm EX-4.5 335093
4 EX-4.6 d382928dex46.htm EX-4.6 42636
5 EX-4.7 d382928dex47.htm EX-4.7 42151
6 EX-5.1 d382928dex51.htm EX-5.1 30825
7 EX-23.1 d382928dex231.htm EX-23.1 2023
8 EX-FILING FEES d382928dexfilingfees.htm EX-FILING FEES 51084
9 GRAPHIC g382928dsp65.jpg GRAPHIC 3611
10 GRAPHIC g382928dsp65a.jpg GRAPHIC 12459
11 GRAPHIC g382928dsp66.jpg GRAPHIC 3527
12 GRAPHIC g382928g30g73.jpg GRAPHIC 68551
13 GRAPHIC g382928g70d92.jpg GRAPHIC 71957
  Complete submission text file 0001193125-22-250139.txt   1487788
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3ASR | Act: 33 | File No.: 333-267578 | Film No.: 221262426
SIC: 2834 Pharmaceutical Preparations